The turnaround became a cash exit
- WNS returned to 9.5% year-over-year revenue growth in Q1 FY26 after a 0.6% decline in FY25.
- BFSI was the strongest segment, growing 24.1% year over year and reaching 41.5% of Q1 FY26 revenue.
- The weak spot stayed in HCLS, where revenue fell 13.7% year over year after a large healthcare client was lost.
- Capgemini agreed to buy WNS for $76.50 per share in cash, valuing the deal at about $3.3 billion.
- Public deal updates after the last filing say the acquisition closed on October 17, 2025, so the standalone stock case has been resolved.
A recovery, then a sale
WNS was showing a cleaner growth story right before the sale. In Q1 FY26, revenue grew 9.5% year over year. That was a sharp change from the 0.6% decline in FY25. The key detail was that existing clients added $7.2 million of revenue, after existing clients had been a drag in the prior year.
The bull case was simple: the FY25 decline looked more like a large healthcare client problem than a broken company. BFSI, which means banking, financial services, and insurance, grew 24.1% year over year in Q1 FY26. It also became 41.5% of revenue, making it the core of the business.
The bear case did not disappear. HCLS, which means healthcare and life sciences, still fell 13.7% year over year in Q1 FY26. That showed the lost healthcare client was still hurting results. Also, the Capgemini deal capped the stock's upside at the cash offer if it closed.
The main public question has now changed. The internal thesis still framed the Capgemini deal as pending based on the August 2025 10-Q. Later public releases say shareholders approved it, the required court step was cleared, and the acquisition closed on October 17, 2025. That means the old standalone investment case is now mostly a record of what shareholders owned before the cash exit.
People, process, and contracts
WNS made money by taking over business tasks for large companies. These tasks included customer service, finance and accounting, research, analytics, and industry-specific work. Clients paid WNS under long contracts that usually ran 3 to 5 years.
Most revenue came from charging by worker. In fiscal 2025, 72.5% of revenue used a per-full-time-equivalent model, which means clients paid based on the number of workers assigned. Other pricing models included per-transaction at 14.9%, subscription at 4.9%, fixed-price at 4.6%, and outcome-based deals.
The model had real switching costs. Once WNS ran a process, moving it away could be risky, slow, and expensive for the client. The weak point was the same concentration risk: one large HCLS customer served a termination notice on January 31, 2024, and WNS said that loss significantly affected fiscal 2025 revenue growth.
What WNS actually did
Industry-specific services
This was the largest service type at 43.5% of fiscal 2025 revenue. It included work tailored to industries such as insurance, travel, healthcare, shipping, and logistics.
Finance and Accounting
This service line was 20.0% of fiscal 2025 revenue. WNS handled back-office finance tasks that clients could outsource to lower cost and improve control.
Customer Experience Services
This was 18.5% of fiscal 2025 revenue. It included customer contact and support work, often delivered across onshore, nearshore, and offshore centers.
Research and Analytics
This was 12.7% of fiscal 2025 revenue. It helped clients turn data into decisions, and it was closely tied to the broader AI and automation push in business services.
Other services
Other services made up 5.3% of fiscal 2025 revenue. This bucket included smaller shared services outside the main lines.
BFSI took the lead
Segment mix is from the three months ended June 30, 2025. BFSI was the largest segment, while HCLS remained pressured by the lost large healthcare client.
What could have broken the case
Deal break risk
High impact · Low oddsThe August 2025 filing said the Capgemini acquisition still needed shareholder and regulatory approval. If the deal had failed, the stock could have fallen because the cash offer had become the main support for the price. Later public releases say the deal closed on October 17, 2025, so this risk appears resolved for former public shareholders.
Healthcare client loss
High impact · Medium oddsA top five customer in HCLS served a termination notice on January 31, 2024. WNS said this significantly affected fiscal 2025 revenue growth and led to a $30.9 million impairment charge in fiscal 2024. HCLS revenue still fell 13.7% year over year in Q1 FY26.
Client concentration
High impact · Medium oddsWNS depended on a few large clients for a meaningful part of revenue. The healthcare customer loss showed how one account can change the growth story. This is a normal risk in business process outsourcing, but it matters more when growth from existing clients is already uneven.
AI changes the work
Medium impact · Medium oddsAI can help WNS automate work and sell better analytics. It can also reduce the need for some people-heavy outsourcing tasks. The risk is that clients demand lower prices, move work in-house, or shift to a rival with better automation.
Currency squeeze
Medium impact · Medium oddsWNS earned significant revenue in Pound Sterling, Australian Dollar, and Euro. A large share of costs came in Indian Rupee and Philippine Peso. Currency moves could hurt margins even if client demand stayed steady.
In one breath
What did WNS do?
WNS was a business process management company. It ran operations for clients, such as finance tasks, customer service, research, analytics, and industry-specific processes.
Why did Capgemini buy WNS?
Capgemini wanted WNS's deep process knowledge and industry-focused outsourcing base. The deal also fit the broader push toward AI-powered operations services.
What was the biggest issue before the sale?
The biggest issue was whether the business had truly returned to healthy growth. BFSI was growing fast, but HCLS was still falling because WNS lost a large healthcare client.
Is WNS still a standalone public stock?
Public deal updates say the acquisition by Capgemini closed on October 17, 2025. That means WNS is no longer mainly a standalone public equity story for retail investors.